In addition, AgomAb has a lung-restricted ALK5 inhibitor (AGMB-447) in early human testing with aspirations to develop it for ...

To get full control of C-CAR031, AZ is buying out AbelZeta's 50% share of the China development and commercialisation rights ...

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...

The use of AI in oncology has tremendous potential to improve many facets of cancer care, including diagnosis, drug discovery ...

For decades, discovery has relied on "brute force" mass-screening – testing thousands of random compounds hoping one will ...

Sun Pharma has downplayed a rumour that it is in talks to acquire women's health specialist Organon, after a report suggested ...

Eric Bennett, CEO of Frontier Bio, and Boyang Wang, founder of Immortal Dragons, discussed 3D tissue biofabrication and ...

All key players - CMOs, CDMOs, pharmaceutical companies, service and equipment vendors, government, and institutions - ...

Male infertility accounts for about 50% of infertility struggles, but research spending for men accounts for just 7%. That’s ...

The EMA has started its review of Daiichi Sankyo and AstraZeneca's Enhertu as a first-line therapy for HER2-positive breast ...

The Bio-Hermes-002 study, involving 1,000 volunteers aged over 60 in the UK, US and Canada, is using finger-prick testing to ...

The decision means Northern Ireland remains the only country in the UK where patients with this stage of prostate cancer are ...